Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 15/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002382 | 0.85 | GAA (0.50) | MAPK1GRIN2DGRIN3BGRIN1GRIN2A | |
| O-Tolylamine SCHEMBL6579301 | 0.81 | CYP3A4 (0.52) | MAPK1NPC1RAB9AGRIN2DGRIN3B | |
| SCHEMBL31607070 | 0.80 | RAB9A (0.57) | NPC1RAB9ASIGMAR1MAPTMEN1 | |
| SCHEMBL11879308 | 0.80 | RAB9A (0.57) | NPC1RAB9ASIGMAR1MAPTMEN1 | |
| SCHEMBL23843812 | 0.80 | HDAC1 (0.52) | HDAC3HDAC1HDAC2MAPK1NPC1 | |
| SCHEMBL11757742 | 0.80 | HDAC1 (0.50) | HDAC3HDAC1HDAC2MAPK1NPC1 | |
| SCHEMBL11760578 | 0.79 | GAA (0.61) | HDAC3HDAC1HDAC2MAPK1NPC1 | |
| SCHEMBL2003354 | 0.79 | GAA (0.45) | MAPK1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL250263 | 0.79 | HDAC3 (0.64) | HDAC3HDAC1HDAC2MAPK1NPC1 | |
| SCHEMBL1116302 | 0.77 | L3MBTL1 (0.61) | HDAC3HDAC1HDAC2MAPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62201827-A | — | — | None | — | — | JP | disclosed |
| JP-62201824-A | — | — | None | — | — | JP | disclosed |
| JP-1304881-A | — | — | None | — | — | JP | disclosed |
| JP-8176015-A | — | — | None | — | — | JP | disclosed |
| CN-109804010-B | Stabilizers for adhesive, sealant and coating compositions | 科思创德国股份有限公司 | 2021-11-12 | — | — | CN | disclosed |
| US-20120316338-A1 | Methods and Intermediates for the Preparation of Optionally Radio-Labeled Imatinib | SALTER RHYS (CH) | 2012-12-13 | — | — | US | disclosed |
| CN-101198601-B | Methods and intermediates for the preparation of optionally radio-labeled imatinib | NOVARTIS AG | 2011-09-07 | — | — | CN | disclosed |
| US-7960459-B2 | Curable composition | KANEKA CORPORATION (JP) | 2011-06-14 | — | — | US | disclosed |
| EP-1990371-B1 | CURABLE COMPOSITION | KANEKA CORP (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20090299064-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OPTIONALLY RADIO-LABELED IMATINIB | SALTER RHYS | 2009-12-03 | — | — | US | disclosed |
| EP-1896447-A2 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OPTIONALLY RADIO-LABELED IMATINIB | Novartis AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006133904-A2 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OPTIONALLY RADIO-LABELED IMATINIB | NOVARTIS AG (CH) | 2006-12-21 | — | — | WO | disclosed |
| JP-H08176015-A | COMPOSITION CONTAINING IMMUNOGLOBULIN | GREEN CROSS CORP:THE | 1996-07-09 | — | — | JP | disclosed |
| JP-H01304881-A | PRODUCTION OF UROKINASE PRECURSOR | GREEN CROSS CORP:THE | 1989-12-08 | — | — | JP | disclosed |
| JP-S62201824-A | PRODUCTION OF BLOOD COAGULATION FACTOR IX COMPOSITE | GREEN CROSS CORP:THE | 1987-09-05 | — | — | JP | disclosed |
| JP-S62201827-A | PRODUCTION OF IMMUNOGLOBULIN | GREEN CROSS CORP:THE | 1987-09-05 | — | — | JP | disclosed |
| US-3881018-A | Substituted amidophenylguanidine fungicides | BAYER AG | 1975-04-29 | — | — | US | disclosed |
| US-3881018-A | Substituted amidophenylguanidine fungicides | BAYER AG | 1975-04-29 | — | — | US | disclosed |
| US-3869503-A | Substituted amidophenylguanidines | BAYER AG | 1975-03-04 | — | — | US | disclosed |
| US-3869503-A | Substituted amidophenylguanidines | BAYER AG | 1975-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299064-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OPTIONALLY RADIO-LABELED IMATINIB | ABL1, PDGFRB, PDGFRA | HDAC3 4098/4885HDAC1 3941/4885HDAC2 4190/4885 |
| US-20120316338-A1 | Methods and Intermediates for the Preparation of Optionally Radio-Labeled Imatinib | ABL1, PDGFRB, PDGFRA | HDAC3 3967/4885HDAC1 3822/4885HDAC2 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.